Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months

A Case Series of 42 Patients

Krisztina Vas, Anita Altmayer, Lilla Mihályi, Edina Garaczi, Ágnes Kinyó, Eszter Jakobicz, S. Husz, L. Kemény, Z. Bata-Csörgő

Research output: Contribution to journalArticle

Abstract

Background: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU). Methods: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Forty-Two patients (36 female and 6 male) met the study criteria by having CSU and giving positive results in the ASST. Our aim was to assess the clinical efficacy and safety of low-dose oral prednisolone therapy administered to patients with antihistamine-refractory ASST-positive CSU for a few months. Patients were given an initial dose (40 mg/day) of prednisolone until the complete resolution of the symptoms, usually 7-10 days, and then the dose was gradually decreased, as in other autoimmune diseases. Results: Prednisolone therapy lasted for an average of 3.6 months and a complete long-lasting response was achieved in 35 of 42 AIU patients (83.3%). The follow-up period was at least 36 months (3 years) for each AIU patient; the longest follow-up time was 139 months (11.5 years). None of the patients reported any considerable side effects. Conclusion: Based on our results, we suggest that the use of this treatment could be an alternative for the treatment of AIU. Our present results also highlight the need for other therapies in a small percentage of AIU patients. Our results suggest that AIU represents a transient autoimmunity that can be successfully treated with low-dose steroid therapy administered for a few months.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalDermatology
Volume233
Issue number6
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Urticaria
Prednisolone
Therapeutics
Skin Tests
Serum
Histamine Antagonists
Dermatology
Autoimmunity
Autoimmune Diseases
Medical Records
Retrospective Studies
Steroids

Keywords

  • Autoimmune diseases
  • Urticaria

ASJC Scopus subject areas

  • Dermatology

Cite this

Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months : A Case Series of 42 Patients. / Vas, Krisztina; Altmayer, Anita; Mihályi, Lilla; Garaczi, Edina; Kinyó, Ágnes; Jakobicz, Eszter; Husz, S.; Kemény, L.; Bata-Csörgő, Z.

In: Dermatology, Vol. 233, No. 6, 01.04.2018, p. 419-424.

Research output: Contribution to journalArticle

Vas, Krisztina ; Altmayer, Anita ; Mihályi, Lilla ; Garaczi, Edina ; Kinyó, Ágnes ; Jakobicz, Eszter ; Husz, S. ; Kemény, L. ; Bata-Csörgő, Z. / Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months : A Case Series of 42 Patients. In: Dermatology. 2018 ; Vol. 233, No. 6. pp. 419-424.
@article{8151d4245d154889a0fffb0748309fbd,
title = "Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months: A Case Series of 42 Patients",
abstract = "Background: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU). Methods: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Forty-Two patients (36 female and 6 male) met the study criteria by having CSU and giving positive results in the ASST. Our aim was to assess the clinical efficacy and safety of low-dose oral prednisolone therapy administered to patients with antihistamine-refractory ASST-positive CSU for a few months. Patients were given an initial dose (40 mg/day) of prednisolone until the complete resolution of the symptoms, usually 7-10 days, and then the dose was gradually decreased, as in other autoimmune diseases. Results: Prednisolone therapy lasted for an average of 3.6 months and a complete long-lasting response was achieved in 35 of 42 AIU patients (83.3{\%}). The follow-up period was at least 36 months (3 years) for each AIU patient; the longest follow-up time was 139 months (11.5 years). None of the patients reported any considerable side effects. Conclusion: Based on our results, we suggest that the use of this treatment could be an alternative for the treatment of AIU. Our present results also highlight the need for other therapies in a small percentage of AIU patients. Our results suggest that AIU represents a transient autoimmunity that can be successfully treated with low-dose steroid therapy administered for a few months.",
keywords = "Autoimmune diseases, Urticaria",
author = "Krisztina Vas and Anita Altmayer and Lilla Mih{\'a}lyi and Edina Garaczi and {\'A}gnes Kiny{\'o} and Eszter Jakobicz and S. Husz and L. Kem{\'e}ny and Z. Bata-Cs{\"o}rgő",
year = "2018",
month = "4",
day = "1",
doi = "10.1159/000484085",
language = "English",
volume = "233",
pages = "419--424",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months

T2 - A Case Series of 42 Patients

AU - Vas, Krisztina

AU - Altmayer, Anita

AU - Mihályi, Lilla

AU - Garaczi, Edina

AU - Kinyó, Ágnes

AU - Jakobicz, Eszter

AU - Husz, S.

AU - Kemény, L.

AU - Bata-Csörgő, Z.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU). Methods: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Forty-Two patients (36 female and 6 male) met the study criteria by having CSU and giving positive results in the ASST. Our aim was to assess the clinical efficacy and safety of low-dose oral prednisolone therapy administered to patients with antihistamine-refractory ASST-positive CSU for a few months. Patients were given an initial dose (40 mg/day) of prednisolone until the complete resolution of the symptoms, usually 7-10 days, and then the dose was gradually decreased, as in other autoimmune diseases. Results: Prednisolone therapy lasted for an average of 3.6 months and a complete long-lasting response was achieved in 35 of 42 AIU patients (83.3%). The follow-up period was at least 36 months (3 years) for each AIU patient; the longest follow-up time was 139 months (11.5 years). None of the patients reported any considerable side effects. Conclusion: Based on our results, we suggest that the use of this treatment could be an alternative for the treatment of AIU. Our present results also highlight the need for other therapies in a small percentage of AIU patients. Our results suggest that AIU represents a transient autoimmunity that can be successfully treated with low-dose steroid therapy administered for a few months.

AB - Background: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU). Methods: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Forty-Two patients (36 female and 6 male) met the study criteria by having CSU and giving positive results in the ASST. Our aim was to assess the clinical efficacy and safety of low-dose oral prednisolone therapy administered to patients with antihistamine-refractory ASST-positive CSU for a few months. Patients were given an initial dose (40 mg/day) of prednisolone until the complete resolution of the symptoms, usually 7-10 days, and then the dose was gradually decreased, as in other autoimmune diseases. Results: Prednisolone therapy lasted for an average of 3.6 months and a complete long-lasting response was achieved in 35 of 42 AIU patients (83.3%). The follow-up period was at least 36 months (3 years) for each AIU patient; the longest follow-up time was 139 months (11.5 years). None of the patients reported any considerable side effects. Conclusion: Based on our results, we suggest that the use of this treatment could be an alternative for the treatment of AIU. Our present results also highlight the need for other therapies in a small percentage of AIU patients. Our results suggest that AIU represents a transient autoimmunity that can be successfully treated with low-dose steroid therapy administered for a few months.

KW - Autoimmune diseases

KW - Urticaria

UR - http://www.scopus.com/inward/record.url?scp=85040743072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040743072&partnerID=8YFLogxK

U2 - 10.1159/000484085

DO - 10.1159/000484085

M3 - Article

VL - 233

SP - 419

EP - 424

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 6

ER -